COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
28/10/2026
Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock to begin trading on Nasdaq under the ticker symbol “AZR” New executive [...]
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
28/10/2026
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL ® [...]
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
28/10/2026
- 1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 [...]
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
28/10/2026
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
28/10/2026
Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape for NF1-associated cutaneous and plexiform neurofibromas MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Teladoc Health Reports Third Quarter 2026 Results
28/10/2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2026 (“Third Quarter 2026”). [...]
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
28/10/2026
Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Fremont, Calif., Oct. [...]
Jushi Holdings Inc. Reports Third Quarter 2026 Financial Results
28/10/2026
Revenue Increased 7% Year-over-Year to $70.5 Million, With Growth Across Wholesale and Retail Channels Wholesale Revenue Increased 40% Year-Over-Year to $9.7 Million, Setting Second Consecutive Quarterly Record Virginia [...]
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
28/10/2026
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
BayCare Selected as a National Best Workplace for Women
28/10/2026
CLEARWATER, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Great Place to Work® and Fortune magazine have selected BayCare for the 2026 Fortune Best Workplaces for Women™ list, marking the sixth time BayCare has earned a spot [...]
NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper
28/10/2026
Partners with HyperLight to integrate thin-film molecular qubits onto advanced photonic integrated circuits, paving the way for a new architecture that delivers quantum computing at scale NVision Unveils First [...]
RYBREVANT®▼ (amivantamab) sous-cutané affiche un taux de réponse objective de 77 pour cent en traitement de première ligne chez des patients atteints de certaines formes avancées de cancer de la tête et du cou
28/10/2026
Des réponses complètes ont été observées chez 14 pour cent des patients atteints d’un carcinome épidermoïde de la tête et du cou (CETC) autre qu’un carcinome épidermoïde de l’oropharynx (CEOP) associé au papillomavirus [...]
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
28/10/2026
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial [...]
Curabotics Enters National Contract with Capstone Health Alliance, Bringing Robotics and Automation to Hundreds of Hospitals
28/10/2026
Unique agreement gives Capstone's member network direct access to Curabotics' proven automation solutions JACKSONVILLE, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Curabotics , a healthcare technology company dedicated to [...]
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
28/10/2026
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage [...]
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
28/10/2026
ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary session AX-0810 Phase 1 data to be featured in two poster presentations at [...]
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
28/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental [...]
MaxCyte to Participate in Three Upcoming Investor Conferences
28/10/2026
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of [...]
Spectral AI Schedules 2026 Third Quarter Financial Results and Conference Call
28/10/2026
DALLAS, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum